Clinical trials: Vulvovaginitis
Recurrent Vulvovaginal Candidiasis
A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC)
This is a prospective, randomized, multi-center, active-controlled, double-blind, double-dummy, multicenter, non-inferiority study comparing the clinical efficacy, safety and tolerability of ProF-001 to fluconazole.
- Trial name
- NCT04734405
- Testing
- Prof-001, Fluconazole 150 mg
- Where
- 29 sites in Austria, Poland and 1 more
- Volunteers
- 432 people
- Sponsor
- ProFem GmbH
Vulvovaginal Candidiasis
Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis
This is a randomized, multicenter, evaluator blinded study to evaluate the safety, tolerability, efficacy and pharmacokinetics of SCY-078 compared to Fluconazole in adult patients with moderate to severe Vulvovaginal Candidiasis…
- Trial name
- NCT02679456
- Testing
- SCY-078, Fluconazole
- Where
- 2 sites in Dominican Republic
- Volunteers
- 96 people
- Sponsor
- Scynexis, Inc.
Vulvovaginal Candidiasis, Candida Infection
Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp
This is a pharmacokinetic evaluation of lactating women after receiving two doses of Ibrexafungerp. The study population included healthy lactating females who were at least 10 days postpartum with a fully established milk supply…
- Conditions
- Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis
- Trial name
- NCT06954493
- Testing
- Ibrexafungerp
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Scynexis, Inc.
Vulvovaginal Candidiasis
Efficacy and Safety of Different Doses of Venus Association in Patients With Vulvovaginal Candidiasis.
The purpose of this study is to evaluate the efficacy and safety of different doses of Venus association in the treatment of vulvovaginal candidiasis.
- Trial name
- NCT05031481
- Testing
- Venus 20 + 0,064, Venus 20 + 1, Venus 20 + 4
- Sponsor
- EMS
Vulvovaginal Candidiasis
Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
This study will treat subjects with complicated VVC who have failed prior fluconazole therapy with Ibrexafungerp for 1, 3 or 7 days of treatment.
- Trial name
- NCT05399641
- Testing
- Ibrexafungerp
- Where
- 25 sites in United States
- Volunteers
- 150 people
- Sponsor
- Scynexis, Inc.
Vulvovaginal Candidiases, Yeast Infection
Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis
This is a single-center, open-label, pilot study to evaluate the efficacy of 14 days of CAMB dosing in subjects with fluconazole-resistant vulvovaginal candidiasis (VVC).
- Conditions
- Vulvovaginal Candidiases, Yeast Infection, Vulvovaginitis, Yeast Infection Vaginal
- Trial name
- NCT03167957
- Testing
- Oral Encochleated Amphotericin B (CAMB)
- Where
- United States
- Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
Candidiasis, Vulvovaginal
Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis
The trial medicinal product (Lcr Regenerans®) is obtained from the culture of a strain of Lactobacillus rhamnosus Lcr35®. By virtue of the freeze-drying technique, Lactobacillus rhamnosus Lcr35® is a live bacterium administered…
- Trial name
- GYNOCANS (NCT02251093)
- Testing
- Lcr Regenerans
- Where
- France
- Volunteers
- 350 people
- Sponsor
- Probionov
Recurrent Vulvovaginal Candidiasis
A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis
The purpose of this study is to evaluate the Efficacy and Safety of SHR8008 capsule In Subjects With Recurrent Vulvovaginal Candidiasis
- Trial name
- NCT05074602
- Testing
- SHR8008, Fluconazole
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Bacterial Vaginosis, Vulvovaginal Candidiasis
TOL-463 Phase 2 Study for Vaginitis
This is a Phase II study designed to assess the safety and efficacy of an investigational product, TOL-463, to treat vaginitis.
- Trial name
- NCT02866227
- Testing
- TOL-463
- Where
- 2 sites in United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Toltec Pharmaceuticals, LLC
Vulvovaginal Candidiases, Vulvovaginal Candidiasis, Genital
Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis
This is a Phase 3 clinical study to evaluate the efficacy, safety, and tolerability of boric acid 600 mg vaginal inserts in patients with VVC.
- Conditions
- Vulvovaginal Candidiases, Vulvovaginal Candidiasis, Genital, Vulvovaginal Candidiasis (VVC)
- Trial name
- NCT07109869
- Testing
- Boric acid
- Where
- 26 sites in United States
- Volunteers
- 333 people
- Sponsor
- pH-D Feminine Health LLC